Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis

Published 26/09/2022, 16:02
Updated 26/09/2022, 16:41
© Reuters. Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis

  • Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from the ARRECTOR Pivotal Phase 3 trial of roflumilast foam 0.3% for treating adults and adolescents with scalp and body psoriasis.
  • The study met its co-primary endpoints of Scalp-Investigator Global Assessment (S-IGA) Success, Body-Investigator Global Assessment (B-IGA) Success, and all secondary endpoints.
  • About 67.3% of individuals treated with roflumilast foam achieved S-IGA Success compared to 28.1% of individuals treated with a matching vehicle foam at week 8.
  • Related: Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics.
  • About 46.5% of individuals treated with roflumilast foam achieved B-IGA Success compared to 20.8% of individuals treated with matching vehicle foam.
  • Roflumilast foam also demonstrated statistically significant improvements compared to the vehicle on all secondary endpoints, including scalp itch.
  • Roflumilast foam was well-tolerated, and the overall safety and tolerability profile were consistent with previously published studies.
  • The company has already announced plans to submit a marketing application to the FDA for roflumilast foam for seborrheic dermatitis in Q1 of 2023.
  • Arcutis believes that the results from the ARRECTOR study should provide sufficient bases for a supplemental marketing application.
  • Price Action: ARQT shares are up 4.95% at $19.09 on the last check Monday.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.